Sunday, November 17, 2019


Here is a submission by Kirtan on Luspatercept!

Luspatercept (recombinant fusion protein containing Activin receptor type IIB moeity) blocks excessive SMAD2/3 activity (Mothers against decapentaplegic homolog) lying downstream of TGF-beta signalling by binding endogenous TGF-beta family members, including Bone morphogenetic proteins (BMP), Activin, Inhibin, Lefty A/B, Artemin, Persephin, GDF, GDNF and MIS.

Ultimately, it facilitates differentiation of normoblasts and myeloblasts into their respective mature forms by removing inhibitory influence from SMAD2/3 thereby abrogating ineffective myelopoeisis and erythropoiesis, approved for Beta Thalassemia and Myelodysplastic syndrome.

Along the spectrum of Azacitidine, Vorinostat, Ivosidenib, Tretinoin and Sirtuins... All being maturing agents!

Seems fantasy, but is reality.... Above and beyond... Exquisite stuff!!

-Kirtan Patolia

No comments:

Post a Comment

This is express yourself space. Where you type create something beautiful! <3
Wondering what do I write? Well...
Tell us something you know better. You are a brilliant mind. Yes, you are! ^__^
Ask about something you don't understand @_@?
Compliment... Say something nice! =D
Be a good critic and correct us if something went wrong :|
Go ahead. Comment all you like here! (:

PS: We have moderated comments to reduce spam. ALL comments that are not spam will be published on the website.